Media headlines about Myriad Genetics (NASDAQ:MYGN) have trended somewhat positive recently, Accern reports. The research firm identifies negative and positive media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Myriad Genetics earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.080110004088 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

A number of equities analysts recently weighed in on the stock. Cowen reaffirmed a “hold” rating and set a $25.00 price objective on shares of Myriad Genetics in a research report on Sunday, September 17th. Leerink Swann reaffirmed a “market perform” rating and set a $31.00 price objective on shares of Myriad Genetics in a research report on Monday, October 2nd. Deutsche Bank raised their price target on shares of Myriad Genetics from $28.00 to $30.00 and gave the company a “hold” rating in a research report on Wednesday, November 8th. Stephens reissued an “overweight” rating and issued a $40.00 price target (up previously from $36.00) on shares of Myriad Genetics in a research report on Friday, September 22nd. Finally, ValuEngine cut shares of Myriad Genetics from a “buy” rating to a “hold” rating in a research report on Thursday, November 2nd. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and two have issued a buy rating to the company’s stock. Myriad Genetics presently has an average rating of “Hold” and a consensus target price of $28.10.

Shares of Myriad Genetics (MYGN) traded down $0.25 on Friday, hitting $34.35. 463,783 shares of the stock were exchanged, compared to its average volume of 670,105. Myriad Genetics has a fifty-two week low of $15.15 and a fifty-two week high of $37.30. The firm has a market cap of $2,378.08, a price-to-earnings ratio of 23.05, a price-to-earnings-growth ratio of 2.18 and a beta of 0.25. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.34 and a quick ratio of 2.06.

Myriad Genetics (NASDAQ:MYGN) last announced its quarterly earnings data on Tuesday, November 7th. The company reported $0.26 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.21 by $0.05. Myriad Genetics had a net margin of 13.28% and a return on equity of 9.54%. The business had revenue of $190.20 million for the quarter, compared to analyst estimates of $183.52 million. During the same period last year, the business earned $0.23 EPS. The company’s revenue was up 7.2% on a year-over-year basis. equities research analysts expect that Myriad Genetics will post 1.05 EPS for the current year.

In related news, insider Alexander Ford sold 3,031 shares of Myriad Genetics stock in a transaction on Monday, November 13th. The shares were sold at an average price of $31.64, for a total transaction of $95,900.84. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Walter Phd Gilbert sold 7,500 shares of Myriad Genetics stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $33.19, for a total transaction of $248,925.00. The disclosure for this sale can be found here. Insiders sold a total of 16,531 shares of company stock worth $545,826 over the last 90 days. Company insiders own 6.70% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was first published by Daily Political and is the property of of Daily Political. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Insider Buying and Selling by Quarter for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with's FREE daily email newsletter.